Medigene AG Company Description

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer.

The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications.

Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications.

The company also develops MDG2011, MDG2021, MDG2012, MDG20XX, and MDG10xx to treat multiple solid tumors.

It has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors.

It has operations in Germany, the United States, and Asia. The company has a research collaboration agreement with WuXi Biologics to design and co-research TCR-guided T Cell engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors; and strategic co-development agreement with EpimAb Biotherapeutics, Inc. to research and develop off-the-shelf TCR-guided T Cell Engagers for the treatment of immune-related disorders, such as solid tumors.

Medigene AG was founded in 1994 and is headquartered in Munich, Germany.

Medigene AG

Country	Germany
Founded	1994
Industry	Biological Products, Except Diagnostic Substances
Employees	76
CEO	Selwyn Ho

Contact Details

Address: Lochhamer Strasse 11 Munich, 82152 Germany
Phone	49 89 2000 330
Website	medigene.com

Stock Details

Ticker Symbol	MDG1
Exchange	Frankfurt Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	EUR
SIC Code	2836

Key Executives

Name	Position
Selwyn Ho	Chief Executive Officer
Birger Kohlert	Chief Financial Officer
Pamela Keck	Head of Investor Relations